ArticlePharmaceuticals (Basel, Switzerland)2021
Doxycycline Attenuates Cancer Cell Growth by Suppressing NLRP3-Mediated Inflammation.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05521048 (Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Transcriptional Cytokine Responses Linked to Pathological Outcomes in Broiler Chickens Fed Residual Doses of Antimicrobials.International journal of molecular sciences · 2026Article
- Differential Modulation of JAK/STAT3 Signaling and BCL-2 Family Proteins by Tetracycline Analogues in Leukemia Models.Pharmaceutics · 2026Article
- Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2024Review
- Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024Review
- The role of NLRP3 inflammasome in aging and age-related diseases.Immunity & ageing : I & A · 2024Review
- TAK1 inhibition mitigates intracerebral hemorrhage-induced brain injury through reduction of oxidative stress and neuronal pyroptosis via the NRF2 signaling pathway.Frontiers in immunology · 2024Article
- Magic bullets, magic shields, and antimicrobials in between.Pharmaceutical science advances · 2023Review
- Article
- Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells.International journal of molecular sciences · 2022Article
- Follistatin-like 1 ameliorates severe acute pancreatitis associated lung injury via inhibiting the activation of NLRP3 inflammasome and NF-κB pathway.American journal of translational research · 2022Article
- Classification of pyroptosis patterns and construction of a novel prognostic model for prostate cancer based on bulk and single-cell RNA sequencing.Frontiers in endocrinology · 2022Article
- Perspectives on the mechanism of pyroptosis after intracerebral hemorrhage.Frontiers in immunology · 2022Review
- Pyroptosis: A new insight of non-small-cell lung cancer treatment.Frontiers in oncology · 2022Review
- Role of Integrin αvβ3 in Doxycycline-Induced Anti-Proliferation in Breast Cancer Cells.Frontiers in cell and developmental biology · 2022Article
- Bilateral Paraventricular Nucleus Upregulation of Extracellular Superoxide Dismutase Decreases Blood Pressure by Regulation of the NLRP3 and Neurotransmitters in Salt-Induced Hypertensive Rats.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
NLR family pyrin domain containing 3 (NLRP3) inflammasome formation is triggered by the damaged mitochondria releasing reactive oxygen species. Doxycycline was shown to regulate inflammation; however, its effect on NLRP3 in cancer remains largely unknown. Therefore, we sought to determine the effect of doxycycline on NLRP3 regulation in cancer using an in vitro model. NLRP3 was activated in a prostate cancer cell line (PC3) and a lung cancer cell line (A549) before treatment with doxycycline. Inflammasome activation was assessed by analyzing RNA expression of NLRP3, Pro-CASP-1, and Pro-IL1β using RT-qPCR. Additionally, NLPR3 protein expression and IL-1β secretion were analyzed using Western blot and ELISA, respectively. Tumor cell viability was determined using Annexin V staining and a cell proliferation assay. Cytokine secretion was analyzed using a 41Plex assay for human cytokines. Data were analyzed using one-way ANOVA model with Tukey's post hoc tests. Doxycycline treatment decreased NLRP3 formation in PC3 and A549 cells compared to untreated and LPS only treated cells (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.